Literature DB >> 7606350

Characterization of kinin receptors modulating neurogenic contractions of the mouse isolated vas deferens.

J Maas1, G A Rae, J P Huidobro-Toro, J B Calixto.   

Abstract

1. This study analyses the receptors mediating the effects of bradykinin (BK) and analogues on neurogenic twitch contractions of the mouse isolated vas deferens evoked, in the presence of captopril (3 microM), by electrical field stimulation with trains of 4 rectangular 0.5 ms pulses of supramaximal strength, delivered at a frequency of 10 Hz every 20 s. 2. BK (0.1-300 nM) induced a graded potentiation of twitches, with an EC50 (geometric mean and 95% confidence limits) of 4.5 nM (1.7-11.6) and an Emax of 315 +/- 19 mg per 10 mg of wet tissue (n = 6). Similar results were obtained in tissues challenged with Lys-BK, [Hyp3]-BK, Met,Lys-BK and the selective B2 receptor agonist [Tyr(Me)8]-BK (0.1-300 nM). 3. The selective B2 receptor antagonists, Hoe 140 (1-10 nM) and NPC 17731 (3-30 nM), caused graded rightward shifts of the curve to BK-induced twitch potentiation, yielding apparent pA2 values of 9.65 +/- 0.09 and 9.08 +/- 0.13, respectively, and Schild plot slopes not different from 1. Both antagonists (100 nM) failed to modify similar twitch potentiations induced by substance P (3 nM) or endothelin-1 (1 nM). Preincubation with the selective B1 receptor antagonist, [Leu8,des-Arg9]-BK (1 microM), increased the potentiating effect of BK on twitches at 30-300 nM. 4. In contrast to BK, the selective B1 receptor agonist, [des-Arg9]-BK (0.3-1000 nM) reduced the amplitude of twitches in a graded fashion, with an IC50 of 13.7 nM (10.4-16.1) and an Imax of 175 +/- 11 mg (n = 4). The twitch depression induced by [des-Arg9]-BK (300 nM) was not affected by Hoe140 (30nM) or NPC 17731 (100nM), but was abolished by the selective B1 receptor antagonist,[Leu8,des-Arg9]-BK (1 microM), which did not modify the twitch inhibitory effect of clonidine (1 nM) or morphine (300 nM).5. In non-stimulated preparations, BK (100 nM) also potentiated, in a Hoe 140-sensitive (10 nM)manner, the contractions induced by ATP (100 microM), but not by noradrenaline (10 microM), whereas[des-Arg9]-BK (300 nM) did not modify the contractions induced by either agonist.6. It is concluded that the mouse vas deferens expresses both B1 and B2 receptors, which modulate sympathetic neurotransmission in opposing ways. Neurogenic contractions are inhibited by stimulation of possibly prejunctional B, receptors, whereas activation of B2 receptors increases twitch contractions,in part by amplifying the responsiveness of the smooth muscle cells to the sympathetic co-transmitter ATP.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7606350      PMCID: PMC1510279          DOI: 10.1111/j.1476-5381.1995.tb13372.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  32 in total

Review 1.  Bradykinin receptors: pharmacological properties and biological roles.

Authors:  J M Hall
Journal:  Pharmacol Ther       Date:  1992-11       Impact factor: 12.310

Review 2.  Bioregulation of kinins: kallikreins, kininogens, and kininases.

Authors:  K D Bhoola; C D Figueroa; K Worthy
Journal:  Pharmacol Rev       Date:  1992-03       Impact factor: 25.468

3.  Analysis of the antagonistic actions of HOE 140 and other novel bradykinin analogues on the guinea-pig ileum.

Authors:  T Griesbacher; F Lembeck
Journal:  Eur J Pharmacol       Date:  1992-02-18       Impact factor: 4.432

4.  New, long-acting, potent bradykinin antagonists.

Authors:  F Lembeck; T Griesbacher; M Eckhardt; S Henke; G Breipohl; J Knolle
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

5.  Bradykinin modulates the release of noradrenaline from vas deferens nerve terminals.

Authors:  I Llona; X Galleguillos; J Belmar; J P Huidobro-Toro
Journal:  Life Sci       Date:  1991       Impact factor: 5.037

6.  Effects of suramin and alpha, beta-methylene ATP indicate noradrenaline-ATP co-transmission in the response of the mouse vas deferens to single and low frequency pulses.

Authors:  I von Kügelgen; R Bültmann; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-12       Impact factor: 3.000

7.  Pharmacological characterization of a new highly potent B2 receptor antagonist (HOE 140: D-Arg-[Hyp3,Thi5,D-Tic7,Qic8]bradykinin).

Authors:  N E Rhaleb; N Rouissi; D Jukic; D Regoli; S Henke; G Breipohl; J Knolle
Journal:  Eur J Pharmacol       Date:  1992-01-14       Impact factor: 4.432

8.  Bradykinin receptors in the guinea-pig taenia caeci are similar to proposed BK3 receptors in the guinea-pig trachea, and are blocked by HOE 140.

Authors:  J L Field; J M Hall; I K Morton
Journal:  Br J Pharmacol       Date:  1992-02       Impact factor: 8.739

9.  ATP overflow from the mouse isolated vas deferens.

Authors:  M E Drake; S A Petersen
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

10.  Bradykinin facilitates the purinergic motor component of the rat bladder neurotransmission.

Authors:  C G Acevedo; J Lewin; E Contreras; J P Huidobro-Toro
Journal:  Neurosci Lett       Date:  1990-05-31       Impact factor: 3.046

View more
  3 in total

1.  Interactive contribution of NK(1) and kinin receptors to the acute inflammatory oedema observed in response to noxious heat stimulation: studies in NK(1) receptor knockout mice.

Authors:  A Rawlingson; N P Gerard; S D Brain
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

2.  Up-regulation of kinin B1 receptor in the lung of streptozotocin-diabetic rat: autoradiographic and functional evidence.

Authors:  Rose Mari J Vianna; Brice Ongali; Domenico Regoli; João Batista Calixto; Réjean Couture
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

3.  The longitudinal muscle of rat ileum as a sensitive monoreceptor assay for bradykinin B1 receptors.

Authors:  S Meini; A Lecci; C A Maggi
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.